Antibodies to Heparin-Platelet Factor 4 Complex: Pathogenesis, Epidemiology, and Management of Heparin-Induced Thrombocytopenia in Hemodialysis

American Journal of Kidney Diseases

Volumn 54, Issue 2, 2009, Pages 361-374

  Davenport, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

argatroban; danaparoid; hemodialysis; Heparin induced thrombocytopenia; hirudin

Indexed keywords

HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY;

AGED; ANAMNESIS; CADAVER; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS; HUMAN; INTRAVENOUS CATHETER; LABORATORY TEST; LUNG EMBOLISM; MALE; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

AGED, 80 AND OVER; ANTICOAGULANTS; AUTOANTIBODIES; HEPARIN; HUMANS; MALE; PLATELET FACTOR 4; RENAL DIALYSIS; THROMBOCYTOPENIA;

EID: 67650438920     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.03.012     Document Type: Review

References (88)

1. Warkentin T.E., and Greinacher A. Heparin induced thrombocytopenia: Recognition, treatment, and prevention. Chest 126 suppl 3 (2004) S311-S337
2. Natelson E.A., Lynch E.C., Alfrey Jr. C.P., and Gross J.B. Heparin induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann Intern Med 71 (1969) 1121-1125
3. Chong B.H., and Berndt M.C. Heparin induced thrombocytopenia. Blut 58 (1989) 53-57
4. Nguyên P., Droullé C., and Potron G. Comparison between platelet factor 4/heparin complexes ELISA and platelet aggregation test in heparin-induced thrombocytopenia. Thromb Haemost 74 (1995) 804-805
5. Greinacher A. Heparin-induced thrombocytopenia: Frequency and pathogenesis. Pathophysiol Haemost Thromb 35 (2006) 37-45
6. Bream-Rouwenhorst H.R., and Hobbs R.A. Heparin-dependent antibodies and thrombosis without heparin-induced thrombocytopenia. Pharmacotherapy 28 (2008) 1401-1407
7. Carlsson L.E., Lubenow N., Blumentritt C., et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 13 (2003) 253-258
8. Hong A.P., Cook D.J., Sigouin C.S., and Warkentin T.E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101 (2003) 3049-3051
9. Davenport A. Heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int 8 (2004) 295-303
10. Warkentin T.E. History of heparin induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin Induced Thrombocytopenia. (ed 3) (2004), Dekker, New York, NY 1-23
11. Amiral J., Bridey F., Wolf M., et al. Antibodies to macromolecular platelet factor 4 heparin induced thrombocytopenia: A study of 44 cases. Thromb Haemost 73 (1995) 21-28
12. Ahmad S. Heparin-induced thrombocytopenia: Impact of bovine versus porcine heparin in HIT pathogenesis. Front Biosci 12 (2007) 3312-3320
13. Greinacher A., Juhl D., Strobel U., et al. Heparin-induced thrombocytopenia: A prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5 (2007) 1666-1673
14. Palomo I., Pereira J., Alarcon M., et al. Prevalence of heparin induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal 19 (2005) 189-195
15. Regnault V., de Maistre E., Carteaux J.P., et al. Platelet activation induced by human antibodies to interleukin-8. Blood 101 (2003) 1419-1421
16. Hutchinson C.A., and Dasgupta I. National survey of heparin induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22 (2007) 1680-1684
17. Davenport A. Low molecular weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient hemodialysis treatments. Nephrology (2009) (in press)
18. Matsuo T., and Wanaka K. Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis. Clin Appl Thromb Hemost 14 (2008) 459-464
19. Gregorini G., Bellandi D., Martini G., and Volpi R. Heparin induced thrombocytopenia syndrome and thrombosis in patients undergoing periodic haemodialysis. G Ital Nefrol 19 (2002) 672-692
20. Lasocki S., Piednoir P., Ajzenberg N., Geffroy A., Benbara A., and Montravers P. Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: A retrospective study. Crit Care 12 (2008) R84
21. Hartman V., Malbrain M., Daelemans R., and Meersman P. Zachée P: Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: Safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 104 (2006) c143-c148
22. Davenport A. Sudden collapse during hemodialysis due to immune mediated heparin induced thrombocytopenia. Nephrol Dial Transplant 21 (2006) 1721-1724
23. Charif R., and Davenport A. Heparin-induced thrombocytopenia: An uncommon but serious complication of heparin use in renal replacement therapy. Hemodial Int 10 (2006) 235-240
24. ElChoufani S.E., Bolin P., Waien S., Christiano C.R., Holbert D., and Bode A.P. Platelet adhesion testing may predict early hemodialysis arteriovenous graft and fistula failure in end stage renal failure patients. Clin Appl Thromb Haemost 14 (2008) 399-409
25. Nakamoto H., Shimada Y., Kanno T., Wanaka K., Matsuo T., and Suzuki H. Role of platelet factor 4 heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis. Hemodial Int 9 suppl 1 (2005) S2-S7
26. O'Shea S.I., Lawson J.H., Reddan D., Murphy M., and Ortel T.L. Hypercoagulable states and antihrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38 (2003) 541-548
27. O'Shea S.I., Sands J.L., Nudo S.A., and Ortel T.L. Frequency of anti heparin platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol 69 (2002) 72-73
28. Asmis L.M., Segal J.B., Plantinga L.C., et al. Heparin induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 100 (2008) 498-504
29. Mureebe L., Coats R.D., Silliman W.R., Shuster T.A., Nicholls W.K., and Silver D. Heparin associated antiplatelet antibodies increase morbidity and mortality in haemodialysis patients. Surgery 136 (2004) 848-853
30. Pena de la Vega L., Miller R.S., Benda M.M., et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: A population-based study. Mayo Clin Proc 8 (2005) 995-1000
31. Carrier M., Rodger M.A., Ferguson D., et al. Increased mortality in haemodialysis patients having specific antibodies to the platelet factor 4 heparin complex. Kidney Int 73 (2008) 213-219
32. Davenport A. Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit. Contrib Nephrol 156 (2007) 259-266
33. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M., and American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (ed 8). Chest 133 (2008) 40-380
34. Warkentin T.E., and Greinacher A. Laboratory testing for heparin induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin Induced Thrombocytopenia. (ed 3) (2004), Dekker, New York, NY 313-334
35. Suzuki S., Sakamoto S., Matsuo M., Shimano C., Kuroda T., and Matsuo T. Thrombotic complications in three haemodialysis patients with heparin induced thrombocytopenia type 1. Clin Appl Thromb Hemost 10 (2004) 81-84
36. Neuhaus T.J., Goetschel P., Schmugge M., and Leumann E. Heparin induced thrombocytopenia type II on haemodialysis: Switch to danaparoid. Pediatr Nephrol 14 (2000) 713-716
37. Aster R.H. Heparin-induced immune thrombocytopenia-A clinical or laboratory diagnosis?. J Thromb Haemost 4 (2006) 757-758
38. Kenney B., and Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 133 (2009) 309-314
39. Davenport A. Heparin induced thrombocytopenia during renal replacement therapy in the intensive care unit. Crit Care 12 (2008) 158
40. Chan M., Malynn E., Shaz B., and Uhl L. Utility of consecutive repeat HIT ELISA testing for heparin induced thrombocytopenia. Am J Hematol 83 (2008) 212-217
41. Davenport A. Intradialytic complications during hemodialysis. Hemodial Int 10 (2006) 162-167
42. Davenport A., and Ahmad R. The effect of reuse of cuprophan dialysers on dialysis induced leukopenia and thrombocytopenia. Dial Transplant 17 (1988) 132-134
43. Davenport A. Pyrexia of unknown origin in a hemodialysis patient. Nephrol Dial Transplant Plus 1 (2008) 109-111
44. Kishimoto T.K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358 (2008) 2457-2467
45. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 30 suppl 4 (1998) S20-S27
46. Boon D.M., Van Vliet H.H., Zietse R., and Kappers-Klunne M.C. The presence of antibodies against a PF4-heparin complex in patients on hemodialysis. Thromb Haemost 76 (1996) 480 (ltr)
47. De Sancho M., Lema M.G., Amiral J., and Rand J. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic haemodialysis. Thromb Haemost 75 (1996) 695-696
48. Luzzatto G., Bertoli M., and Cella G. Platelet count, antiheparin/platelet-factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 89 (1998) 115-122
49. Sitter T., Spannagl M., and Banas B. Prevalence of heparin induced PF4-heparin antibodies in hemodialysis patients. Nephron 79 (1998) 245-246
50. Greinacher A., Zinn S., Wizemann S., and Birk U.W. Heparin induced antibodies as a risk for thromboembolism and hemorrhage in patients undergoing hemodialysis. Lancet 348 (1996) 764 (ltr)
51. Yamamoto S., Koide M., and Matsuo M. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 25 (1996) 82-85
52. Warkentin T.E., Sheppard J.I., Moore J.C., Sigouin C.S., and Kelton J.G. The quantitative interpretation of optical density measurements using PF4 dependent enzyme immunoassays. J Thromb Haemost 6 (2008) 1304-1312
53. Davenport A. Central venous catheters for haemodialysis: How to overcome the problems. Hemodial Int 4 (2000) 78-82
54. Warkentin E. Clinical picture of heparin induced thrombocytopenia. In: Warkentin T.E., and Greinacher A. (Eds). Heparin Induced Thrombocytopenia. (ed 3) (2004), Dekker, New York, NY 53-106
55. Keeling D., Davidson S., Watson H., and Hemostasis and Thrombosis Task Force of the British Committee for Standards in Hematology. The management of heparin-induced thrombocytopenia. Br J Haematol 133 (2006) 259-269
56. Lubenow N., Eichler P., Lietz T., Greinacher A., and HIT Investigators Group. Lepirudin in patients with heparin induced thrombocytopenia-Results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2 and HAT-3. J Thromb Haemost 3 (2005) 2428-2436
57. Magnani H.N., and Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 95 (2006) 967-981
58. Roe S.D., Cassidy M.J., Haynes A.P., and Byrne J.L. Heparin induced thrombocytopenia and thrombosis in a haemodialysis dependent patient with systemic vasculitis. Nephrol Dial Transplant 13 (1998) 3226-3229
59. Kramel K., Furll B., Warkentin T.E., et al. Heparin induced thrombocytopenia therapeutic concentrations of danaparoid, unlike fondaprinux and direct thrombin inhibitors inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 6 (2008) 2160-2167
60. Haase M., Bellomo R., Rocktaeschel J., et al. Use of fondaprinux (ARIXTRA) in a dialysis patient with symptomatic heparin induced thrombocytopenia type II. Nephrol Dial Transplant 20 (2005) 444-446
61. Sombolos K.I., Fragia T.K., Gionanlis L.C., et al. Use of fondaparinux as an anticoagulant during hemodialysis: A preliminary study. Int J Clin Pharmacol Ther 46 (2008) 198-203
62. Rota E., Bazzan M., and Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 99 (2008) 779-781
63. Bucha E., Kreml R., and Nowak G. In vitro study of r-hirudin permeability through membranes of different haemodialysers. Nephrol Dial Transplant 14 (1999) 2922-2926
64. Benz K., Nauck M.A., Bohler J., and Fischer K.G. Hemofiltration of recombinant hirudin by different hemodialyzer membranes, implications for clinical use. Clin J Am Soc Nephrol 2 (2007) 470-476
65. Greinacher A., and Warkentin T.E. The direct thrombin inhibitor hirudin. Thromb Haemost 99 (2008) 819-829
66. Eichler P., Friesen H.J., Lubennow N., Jaeger B., and Greinacre A. Antihirudin antibodies in patients with heparin induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance. Blood 96 (2000) 2373-2378
67. Fischer K.G., Liebe V., Hudek R., et al. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 89 (2003) 973-982
68. Warkentin T.E., Greinachre A., and Koster A. Bivalirudin. Thromb Haemost 99 (2008) 830-839
69. Eichler P., Lubenow N., Strobel U., and Greinacher A. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 103 (2004) 613-616
70. Murray P.T., Reddy B.V., Grossman E.J., et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66 (2004) 2446-2453
71. Matsuo T., Kobayashi H., Matsuo M., et al. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. Pathophysiol Haemost Thromb 35 (2006) 445-450
72. Dager W.E., and White R.H. Argatroban for heparin induced thrombocytopenia in hepatorenal failure and CVVHD. Ann Pharmacother 37 (2003) 1232-1236
73. Matsuo T., Kusano H., Wanaka K., Ishihara M., and Oyama A. Heparin induced thrombocytopenia in a uremic patient requiring hemodialysis: An alternative treatment and re-exposure to heparin. Clin Appl Thromb Hemost 13 (2007) 182-187
74. Schenk P., Rosenkranz A.R., Wolff G., Horl W.H., and Traindl O. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming Quinton Permcath. Am J Kidney Dis 35 (2000) 130-136
75. O'Shea S.I., Ortel T.L., and Ovalik E.C. Alternative methods of anticoagulation for dialysis dependent patients with heparin induced thrombocytopenia. Semin Dial 16 (2003) 61-67
76. Davenport A. The management of heparin induced thrombocytopenia during renal replacement therapy. Hemodial Int 3 (2001) 81-85
77. Hall A.V., Clark W.F., and Parbtani A. Heparin induced thrombocytopenia in renal failure. Clin Nephrol 38 (1992) 86-89
78. Matsuo T., Yamada T., Chikahira Y., and Kadowaki S. Effect of aspirin on heparin induced thrombocytopenia (HIT) in a patient requiring haemodialysis. Blut 59 (1989) 393-395
79. Davenport A. Management of heparin-induced thrombocytopenia during continuous renal replacement therapy. Am J Kidney Dis 32 (1998) e1-e5
80. Fiaccadori E., Maggiore U., Parenti E., et al. Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure. Nephrol Dial Transplant 22 (2007) 529-537
81. Davenport A., Will E.J., and Davison A.M. The effect of prostacyclin on intracranial pressure in patients with acute hepatic and renal failure. Clin Nephrol 25 (1991) 151-157
82. Hofbauer R., Moser D., Frass M., et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 56 (1999) 1578-1583
83. Davenport A. Anticoagulation options for intermittent haemodialysis. Minerva Urol Nefrol 58 (2006) 171-180
84. Matsuo T., Matsuo M., and Ouga-Maruyama S. Can nafamostat mesilate be used for temporary management of hemodialysis in a patient with heparin-induced thrombocytopenia (HIT)?. Thromb Haemost 86 (2001) 1115-1116
85. Davenport A. Anticoagulation in heparin induced thrombocytopenia thrombosis syndrome in patients on dialysis. Hosp Pharm Eur 33 (2007) 48-49
86. Ahmed I., Majeed A., and Powell R. Heparin induced thrombocytopenia: A diagnosis and management update. Post Grad Med J 83 (2007) 575-582
87. Davenport A. HIT on dialysis-When is it safe to re-challenge?. Nephron Clin Pract 104 (2006) c149-c150
88. Davenport A. Low molecular weight heparin for routine hemodialysis. Hemodial Int 12 suppl 2 (2008) S34-S37